Table 1.
Demographic and histologic features of Kenyan Wilms tumor
| Patient | Race | Sex | Age at Diagnosis (months) |
Stage at Diagnosis |
Disease Relapse |
Vital Status |
Histology | Nuclear Unrest |
Cellular Predominance |
WT1 | CITED1 | SIX2 | β- Catenin exons 3, 7, 8 |
WT1 | Nuclear β- Catenin in Blastema |
Nuclear β-Catenin in Epithelia |
p53 | Estimated Proliferative index: (proportion Ki67 positive) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | B | M | 25 | 3 | No | Alive | FH | − | Triphasic | + | + | + | wt | wt | + | + | + | 63% |
| 2 | B | M | 9 | ≥2 | No | LTF | FH | − | Triphasic | + | + | + | wt | SNP | + | + | − | 66% |
| 3 | B | M | 60 | * | * | * | UH | N/A | Triphasic | + | + | + | wt | wt | − | − | + | 15% |
| 4 | B | M | 36 | * | * | * | FH | − | Triphasic | + | + | + | wt | wt | + | + | + | 11% |
| 5 | B | M | 48 | 3 | Yes | LTF | FH | − | Blastemal | + | + | + | wt | SNP | + | − | − | 4% |
| 6 | B | F | 48 | * | * | * | FH | − | Blastemal | + | + | − | wt | Wt | + | + | − | 17% |
| 7 | B | M | 30 | 2 | Yes | Dead | FH | + | Blastemal | + | + | + | wt | wt | + | + | − | 24% |
| 8 | B | F | 26 | 2 | No | Alive | FH | + | Triphasic | + | − | − | wt | wt | + | + | − | 34% |
| 9 | B | M | 60 | 3 | Yes | LTF | FH | + | Triphasic | + | − | + | wt | wt | − | + | − | 25% |
| 10 | B | M | 24 | 4 | * | Dead | FH | + | Blastemal | + | + | + | wt | MUT | + | + | − | 15% |
| 11 | B | F | * | ≥3 | * | * | FH | + | Blastemal | + | − | + | wt | wt | + | − | + | 10% |
| 12 | B | F | 48 | * | * | * | FH | + | Blastemal | + | + | − | wt | wt | + | + | + | 46% |
| 13 | B | M | * | 3 | Yes | Dead | FH | + | Triphasic | + | + | + | wt | wt | + | − | − | 5% |
| 14 | B | F | 20 | * | * | * | FH | + | Blastemal | + | + | + | wt | wt | + | − | − | 30% |
| 15 | B | F | 54 | ≥3 | No | Alive | UH | N/A | Blastemal | + | + | + | wt | SNP | + | + | + | 59% |
| Summary Kenyan WT | 100% Black | 60% male | Median = 36 mos | - | ≥4 disease relapse | 20% known alive | 13% UH | 61.5% unrest in FH | 53.3% blastemal | 100% | 80% | 80% | 100% wild-type | 6.7% mutant WT1 | 86.7% nuclear | 66.7% nuclear | 40% positive | Mean = 28% |
| Summary North American WT | 50% Black | 55% male | Median = 29 mos | - | 2 disease relapse | 95% known alive | 5% UH | 5.6% unrest in FH | 45% blastemal | N/A | N/A | N/A | N/A | N/A | 95% nuclear | 20% nuclear | 40% positive | Mean = 23% |
| Comparison‡ | N/A | p=1.00 | p=0.2113 | N/A | p=0.044 | p=0.0013 | p=0.565 | P=0.001 | p=0.738 | N/A | N/A | N/A | N/A | N/A | p=0.560 | p=0.013 | p=1.00 | p=0.790 |
*
Indicates data missing.
‡
Wilcoxon rank sum used for continuous variables, Fisher’s exact test for categorical variables
KWT = Kenyan Wilms Tumor; NAWT = North American Wilms tumor; B = Black; LTF = Lost to follow up; FH = Favorable histology; UH = Unfavorable histology; N/A = not applicable; wt = wild-type; MUT = mutation; SNP = synonymous single nucleotide polymorphism = Minimum stage at presentation (complete data not available)
Staging by COG criteria10